期刊
CELLS
卷 11, 期 21, 页码 -出版社
MDPI
DOI: 10.3390/cells11213482
关键词
LIF; LIFR axis; pancreatic cancer; mifepristone; cyclins; cell cycle; gemcitabine; repositioning
类别
资金
- Italian MIUR/PRIN [2017FJZZRC]
- European Regional Development Fund-POR Campania FESR 2014/2020
- University of Napoli Federico II [FRA-Line B-2020-MoDiGa]
Pancreatic cancer is a leading cause of cancer mortality and limited therapeutic opportunities. In this study, leukaemia inhibitory factor (LIF) and its receptor (LIFR) were identified as potential therapeutic targets. The researchers found that mifepristone, a progesterone/glucocorticoid antagonist, can act as a potent LIFR antagonist and reverse the effects of LIF on pancreatic cancer cell proliferation, migration, and epithelial mesenchymal transition. These findings suggest that mifepristone could be repositioned as a potential therapeutic agent in the treatment of pancreatic cancer.
Pancreatic cancer is a leading cause of cancer mortality and is projected to become the second-most common cause of cancer mortality in the next decade. While gene-wide association studies and next generation sequencing analyses have identified molecular patterns and transcriptome profiles with prognostic relevance, therapeutic opportunities remain limited. Among the genes that are upregulated in pancreatic ductal adenocarcinomas (PDAC), the leukaemia inhibitory factor (LIF), a cytokine belonging to IL-6 family, has emerged as potential therapeutic candidate. LIF is aberrantly secreted by tumour cells and promotes tumour progression in pancreatic and other solid tumours through aberrant activation of the LIF receptor (LIFR) and downstream signalling that involves the JAK1/STAT3 pathway. Since there are no LIFR antagonists available for clinical use, we developed an in silico strategy to identify potential LIFR antagonists and drug repositioning with regard to LIFR antagonists. The results of these studies allowed the identification of mifepristone, a progesterone/glucocorticoid antagonist, clinically used in medical abortion, as a potent LIFR antagonist. Computational studies revealed that mifepristone binding partially overlapped the LIFR binding site. LIF and LIFR are expressed by human PDAC tissues and PDAC cell lines, including MIA-PaCa-2 and PANC-1 cells. Exposure of these cell lines to mifepristone reverses cell proliferation, migration and epithelial mesenchymal transition induced by LIF in a concentration-dependent manner. Mifepristone inhibits LIFR signalling and reverses STAT3 phosphorylation induced by LIF. Together, these data support the repositioning of mifepristone as a potential therapeutic agent in the treatment of PDAC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据